OSI Bullish On Increased Tarceva Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncologic is “entrenched” in the market, not greatly vulnerable to competition from Erbitux, CEO Goddard tells investors.
You may also be interested in...
Through Alimta Lens, OSI Views Positive Near-term Advantages For Tarceva In Lung Cancer
Approval of Lilly’s Alimta in first-line NSCLC and recent data showing it is ineffective in squamous histologies could give Tarceva a leg up in second-line setting.
Through Alimta Lens, OSI Views Positive Near-term Advantages For Tarceva In Lung Cancer
Approval of Lilly’s Alimta in first-line NSCLC and recent data showing it is ineffective in squamous histologies could give Tarceva a leg up in second-line setting.
AstraZeneca’s Recentin Will Move Into Phase III For Colorectal Cancer, But Not NSCLC
Firm will study VEGF inhibitor plus chemotherapy versus Genentech’s Avastin in first-line colorectal cancer.